He Xu

Journal Article Xenotransplantation · 2026 BACKGROUND: Porcine islet xenotransplantation is limited by the availability of clinically applicable immunosuppressive regimens. We tested four depletional induction strategies and maintenance regimens in a non-human primate (NHP) islet xenotransplant mod ... Full text Link to item Cite

Immunomodulation of T cell-mediated alloimmunity by proximity to endothelial cells under the mammalian target of rapamycin blockade.

Journal Article Am J Transplant · February 2025 Endothelial cells (ECs) are an initial barrier between vascularized organ allografts and the host immune system and are thus well positioned to initiate and influence alloimmune rejection. The mammalian target of rapamycin inhibitor rapamycin is known to i ... Full text Link to item Cite

Rapamycin Prevents Expansion of Costimulation Blockade-resistant CD8+ Alloreactive Memory Cells following Depletional Induction in Renal Transplant Recipients.

Journal Article J Immunol · November 1, 2024 Alemtuzumab induction with belatacept/rapamycin-based maintenance immunotherapy (ABR) prevents kidney allograft rejection and specifically limits early costimulation blockade-resistant rejection (CoBRR). To evaluate the mechanisms by which this regimen alt ... Full text Open Access Link to item Cite

View All Publications

Recent Grants

A CD6-targeted antibody conjugate (CD6-ADC) selectively ablates alloreactive proliferating T cells in humans and non-human primates (NHPs)

ResearchInvestigator · Awarded by Massachusetts General Hospital · 2024 - 2027

Neonatal porcine islet xenografts for the treatment of type 1 diabetes

ResearchInvestigator · Awarded by National Institute of Allergy and Infectious Diseases · 2014 - 2026

Phase 2 Study of Belatacept, Alemtuzumab, and Sirolimus in Renal Transplantation

ResearchCo Investigator · Awarded by Food and Drug Administration · 2015 - 2020

View All Grants

Education, Training & Certifications

Hebei Medical College (China) · 1983 M.D.